Pharma Cos. Imara And Enliven Therapeutics Agree To Merger
Arix Bioscience PLC subsidiary Imara Inc. and Enliven Therapeutics Inc. said on Friday they have agreed to merge in an all-stock deal to create a pharmaceutical company valued at approximately $300 million,...To view the full article, register now.
Already a subscriber? Click here to view full article